Iovance Biotherapeutics, Inc. (IOVA)
Company Info
| ISIN | US4622601007 |
|---|---|
| CUSIP | 462260100 |
| Sector | Healthcare |
| Industry | Biotechnology |
Highlights
| Market Cap | $3.16B |
|---|---|
| EPS (TTM) | -$1.67 |
| Total Revenue (TTM) | $32.77M |
| Gross Profit (TTM) | -$34.93M |
| EBITDA (TTM) | -$428.77M |
| Year Range | $3.21 - $18.33 |
| Target Price | $24.42 |
| Short % | 21.02% |
| Short Ratio | 7.85 |
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Popular comparisons: IOVA vs. ATAI, IOVA vs. RARE, IOVA vs. IDYA, IOVA vs. ET, IOVA vs. CORT, IOVA vs. MATW, IOVA vs. AXSM
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Iovance Biotherapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Iovance Biotherapeutics, Inc. had a return of 25.09% year-to-date (YTD) and 87.29% in the last 12 months. Over the past 10 years, Iovance Biotherapeutics, Inc. had an annualized return of 4.10%, while the S&P 500 had an annualized return of 10.85%, indicating that Iovance Biotherapeutics, Inc. did not perform as well as the benchmark.
| Period | Return | Benchmark |
|---|---|---|
| Year-To-Date | 25.09% | 17.79% |
| 1 month | -9.12% | 0.18% |
| 6 months | -31.88% | 7.53% |
| 1 year | 87.29% | 26.42% |
| 5 years (annualized) | -13.49% | 13.48% |
| 10 years (annualized) | 4.10% | 10.85% |
Monthly Returns
The table below presents the monthly returns of IOVA, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -4.92% | 105.82% | -6.85% | -20.51% | -24.62% | -9.68% | 8.85% | 33.56% | 25.09% | ||||
| 2023 | 24.57% | -8.42% | -16.19% | -7.69% | 54.96% | -19.45% | 3.13% | -16.80% | -24.67% | -16.04% | 58.90% | 33.94% | 27.23% |
| 2022 | -12.78% | -5.89% | 6.25% | -9.01% | -55.45% | 63.56% | 5.53% | -7.98% | -10.63% | -2.51% | -31.48% | -0.16% | -66.53% |
| 2021 | -5.52% | -14.92% | -15.12% | -0.69% | -40.94% | 40.12% | -14.41% | 8.08% | 2.45% | -1.42% | -22.99% | 1.98% | -58.86% |
| 2020 | -21.46% | 51.38% | -9.04% | 7.40% | -0.19% | -14.46% | 5.90% | 14.65% | -1.23% | 8.38% | 8.77% | 19.56% | 67.63% |
| 2019 | 3.39% | 12.24% | -7.40% | 19.87% | 43.42% | 49.97% | 0.29% | -14.56% | -13.37% | 16.10% | 8.05% | 21.24% | 212.77% |
| 2018 | 94.37% | 11.58% | -2.59% | -14.20% | 0.69% | -12.33% | 10.94% | 24.65% | -36.44% | -19.29% | 6.50% | -8.48% | 10.62% |
| 2017 | 4.32% | 5.52% | -2.61% | -8.05% | -24.82% | 42.72% | -20.41% | -1.71% | 34.78% | 0.32% | 16.40% | -11.60% | 15.11% |
| 2016 | -22.41% | -6.84% | -8.96% | 11.61% | 4.06% | 37.29% | 9.14% | -9.95% | 3.39% | -24.06% | 6.40% | 4.51% | -9.97% |
| 2015 | -0.25% | 14.39% | 34.86% | -1.49% | -6.20% | -18.05% | -6.65% | -16.94% | -18.99% | 12.33% | 12.52% | 6.04% | -1.91% |
| 2014 | -53.05% | 11.97% | 71.01% | -8.90% | -12.79% | -14.67% | 11.72% | -3.78% | 3.92% | -10.63% | -3.76% | 27.97% | -25.05% |
| 2013 | -50.71% | -30.49% | -20.00% | -71.67% | 188.24% | -66.33% | 300.00% | -16.67% | 19.09% | -27.48% | 77.26% | 24.70% | -52.03% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of IOVA is 71, suggesting that the investment has average results relative to other stocks in terms of risk-adjusted performance. This ranking is determined by the cumulative values of the indicators listed below.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Iovance Biotherapeutics, Inc. (IOVA) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Iovance Biotherapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Iovance Biotherapeutics, Inc. was 99.36%, occurring on May 7, 2013. The portfolio has not yet recovered.
The current Iovance Biotherapeutics, Inc. drawdown is 93.60%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.36% | Jun 8, 2011 | 379 | May 7, 2013 | — | — | — |
| -23.2% | May 27, 2010 | 29 | Nov 19, 2010 | 7 | Dec 31, 2010 | 36 |
| -12.7% | Mar 9, 2011 | 2 | Mar 14, 2011 | 23 | Apr 29, 2011 | 25 |
| -6.99% | May 26, 2011 | 3 | May 31, 2011 | 1 | Jun 1, 2011 | 4 |
| -6.3% | May 2, 2011 | 2 | May 3, 2011 | 9 | May 17, 2011 | 11 |
Volatility
Volatility Chart
The current Iovance Biotherapeutics, Inc. volatility is 18.93%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Historical P/E Ratio Chart
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Iovance Biotherapeutics, Inc..
Loading data...
Income Statement
| TTM | |
|---|---|
| Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
| Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
| Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |